

CMV

Selected References:

- Alder SP and Nigro G. 2013. Prevention of maternal-fetal transmission of cytomegalovirus. *Clinical Infectious Diseases* 57(S4):S189-S192.
- American College of Obstetricians and Gynecologists. 2015. Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. *Obstet Gynecol.* 125(6):1510-25.
- Azam A, et al. 2001. Prenatal diagnosis of congenital cytomegalovirus infection. *Obstet Gynecol* 97:443-448.
- Balegamire SJ, et al. 2024. Association Between Maternal Cytomegalovirus Seropositivity, Preterm Birth, and Preeclampsia in Two Cohorts From Quebec, Canada: A Mediation Analysis. *Am J Reprod Immunol.*;92(4):e13941.
- Barlinn R, et al. 2022. Maternal cytomegalovirus infection and delayed language development in children at 3 years of age—a nested case-control study in a large population-based pregnancy cohort. *PLoS ONE* 17(12):e0278623.
- Boppana SB et al. 2013. Congenital cytomegalovirus infection: clinical outcome. *Clinical Infectious Diseases* 57(S4):S178-181.
- Carlson A, et al. 2010. Cytomegalovirus infection in pregnancy: Should all women be screened? *Reviews in OB & GYN*; 3(4):172-179.
- Centers for Disease Control and Prevention (CDC). 2016. Handwashing. Available at: <https://www.cdc.gov/handwashing/when-how-handwashing.html>.
- Centers for Disease Control and Prevention (CDC). 2018. Cytomegalovirus (CMV) and Congenital CMV Infection. Available at: <https://www.cdc.gov/cmv/clinical/features.html>.
- Centers of Disease Control and Prevention (CDC). 2020. About cytomegalovirus and congenital CMV infection.
- Chatzakis C, et al. 2020. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. *Am J Obstet Gynecol.* 223(6):870-883.e11.
- Chiopris G, et al. 2020. Congenital Cytomegalovirus Infection: Update on Diagnosis and Treatment. *Microorganisms* Oct 1;8(10):1516.
- Cito G, et al. 2020. Can cytomegalovirus infection affect male reproductive function? Results of a retrospective single-centre analysis. *Andrologia*; 52(9):e13699.
- Diav-Citrin O, et al. 2003. Cytomegalovirus in pregnancy: primary versus secondary infection: a prospective cohort study on 208 pregnancies. *Birth Defects Res Part A Clin Mol Teratol*;67:392.
- Demmler-Harrison GJ, Miller JA. 2020. Houston Congenital Cytomegalovirus Longitudinal Study Group. Maternal cytomegalovirus immune status and hearing loss outcomes in congenital cytomegalovirus-infected offspring. *PLoS One*.15(10):e0240172.
- Enders G, et al. 2001. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. *Prenat Diag* 21: 362-377.
- Grazia Revello M, et al. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. *NEJM*; 370:14: 1316-26.
- Farsimadan M, Motamedifar, 2021. The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. *Br J Biomed Sci*;78(1):1-11.
- Feldman DM, et al. 2010. Toxoplasmosis, parvovirus and cytomegalovirus in pregnancy. *Clin Lab Med* 30(3):709-720.
- Foulon I, et al. 2008. Hearing loss in children with congenital cytomegalovirus infection in relation to maternal trimester in which the maternal primary infection occurred. *Pediatrics* 122(6):e1123-e1127.
- Fowler KB, et al. 2003. Congenital cytomegalovirus infection. *Curr Probl Pediatr Adolesc Health Care* 33:70-93.
- Fowler KB. 2013. Congenital cytomegalovirus infection: audiologic outcome. *Clinical Infectious Diseases*

57(S4):S182-S184.

- Harnprecht K, et al. 2001. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. *Lancet* 357:513-8.
- Hughes BL, et al. 2021. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. *N Engl J Med*. 385(5):436-444.
- Iwasenko JM, et al. 2011. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. *The Journal of Infectious Diseases* 203(11):1526-1533.
- James SH, Kimberlin DW. 2016. Advances in the prevention and treatment of congenital cytomegalovirus infection. *Curr Opin Pediatr*. 28(1):81-5.
- Kagan KO, et al. 2021. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. *Ultrasound Obstet Gynecol*. 57(4):560-567.
- Kirschen GW, Burd I. 2023. Modeling of vertical transmission and pathogenesis of cytomegalovirus in pregnancy: Opportunities and challenges. *Front Virol*; 3:1106634.
- Leruez-Ville M, et al. 2020. Quantifying the Burden of Congenital Cytomegalovirus Infection With Long-term Sequelae in Subsequent Pregnancies of Women Seronegative at Their First Pregnancy. *Clin Infect Dis*. 71(7):1598-1603.
- Lipitz S, et al. 2002. Outcome of pregnancies with vertical transmission of primary cytomegalovirus infection. *Am J Obstet Gynecol*: 100:428-33.
- Mocanu AG, et al. 2024. The Impact of Latent Cytomegalovirus Infection on Spontaneous Abortion History and Pregnancy Outcomes in Romanian Pregnant Women. *Microorganisms*;12(4):731.
- Mestas E. 2016. Congenital cytomegalovirus. *Adv Neonatal Care*. 16(1):60-5.
- National CMV Foundation. 2023. *For healthcare providers*. Physician and OB-GYN Resources, National CMV Foundation, National CMV Foundation.
- National CMV Foundation. 2023. *Possible outcomes*. Congenital CMV Outcomes, National CMV Foundation, National CMV Foundation.
- Nigro G, et al. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. *N Engl J Med* 353:1350-1362.
- Nigro G. 2017. Hyperimmune globulin in pregnancy for the prevention of congenital cytomegalovirus disease. *Expert Rev Anti Infect Ther* 15(11):977-986.
- Nigro G and Alder SP. 2013. Hyperimmunoglobulin for prevention of congenital cytomegalovirus disease. *Clinical Infectious Diseases* 57(S4):S193-S195.
- Ornoy A and Diav-Citrin O. 2006. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. *Reprod Toxicol* 21:399-409.
- Oliveira GM, et al. 2019. Detection of cytomegalovirus, herpes virus simplex, and parvovirus b19 in spontaneous abortion placentas. *J Matern Fetal Neonatal Med*.32(5):768-775.
- Page JM, et al. 2019. Stillbirth Associated With Infection in a Diverse U.S. Cohort. *Obstet Gynecol* 134(6):1187-1196.
- Pereira L, et al. 2014. Intrauterine growth restriction causes by underlying congenital cytomegalovirus infection. *J Infect Disease* 209: 1573-1584.
- Pesch MH, et al. 2021. Cytomegalovirus Infection in Pregnancy: Prevention, Presentation, Management and Neonatal Outcomes. *J Midwifery Womens Health*. 66(3):397-402.
- Pesch MH, et al. 2024. Intrauterine Fetal Demise, Spontaneous Abortion and Congenital Cytomegalovirus: A Systematic Review of the Incidence and Histopathologic Features. *Viruses*; 16(10):1552.
- Picone O, et al. 2013. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcomes. *Prenatal Diag* 33: 751-758.
- El-Qushayri AE, et al 2020. Hyperimmunoglobulin therapy for the prevention and treatment of congenital cytomegalovirus: a systematic review and meta-analysis. *Expert Rev Anti Infect Ther*. Nov 30;1-9.
- Saade GR 2020. The effect of treatment of maternal CMV infection on the development of placental syndrome.

AJOG 222(1) Supp:S2-3.

- Seidenari A, et al. 2024. Follow-Up of Infants With Congenital Cytomegalovirus Following Maternal Primary Infection in the First Trimester and Normal Fetal Brain Imaging at Midgestation. *Prenat Diagn*; 45(2):178-184.
- Simonazzi G, et al. 2018. Perinatal outcomes of non-primary maternal cytomegalovirus infection: A 15-year experience. *Fetal Diagn Ther*. 43(2):138-142.
- Sorrenti S, et al. 2025. Diagnosis and management of congenital Cytomegalovirus: Critical Appraisal of Clinical Practice Guidelines. *Eur J Obstet Gynecol Reprod Biol*; 306:172-180.
- Williams EJ, et al. 2013. Viral infections: contributions to late fetal death, stillbirth, and infant death. *J Pediatr* 163(2): 424-428.
- Yinon T et al. 2010. Cytomegalovirus infection in pregnancy. *J Obstet Gynaecol Can* 32(4):348-354.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

CMV

Selected References:

- Ackerman JP, et al. 2010. A review of the effects of prenatal cocaine exposure among school-aged children. *Pediatrics* 125(3):554-565.
- Akyuz N, et al. 2014. Structural brain imaging in children and adolescents following prenatal cocaine exposure: preliminary longitudinal findings. *Dev Neurosci*. 316-28.
- Behnke M, et al. 2001. The search for congenital malformations in newborns with fetal cocaine exposure. *Pediatrics* 107(5):E74.
- Bracken MB, et al. 1990. Association of cocaine use with sperm concentration, motility, and morphology. *Fertil Steril* 53:315-322
- British Columbia Reproductive Care Program. 1999. Substance Use Guideline 5B: Prenatal Cocaine Exposure, Care of the Newborn. Retrieved from:

www.perinataleservicesbc.ca/Documents/Guidelines-Standards/Newborn/CocaineExposureNewbornCareGuideline.pdf.

- Cestonari, C, et al. 2022. Infants of mothers with cocaine use: Review of clinical and medico-legal aspects. *Children* 9(1):67-84.
- Chiriboga C, et al. 2007. Prenatal cocaine exposures and dose-related cocaine effects on infant tone and behavior. *Neurotoxicol Teratol* 29: 323-330.
- Chiriboga CA, et al. 2009. Prenatal cocaine exposure and prolonged focus attention. Poor infant information processing ability or precocious maturation of attentional systems? *Dev Neurosci* 31(1-2):149-158.
- Cone EJ, et al. 1996. Cocaine excretion in the semen of drug users. *J Anal Toxicol* 20:139-140.
- De Genna, N. M., Goldschmidt, L., & Richardson, G. A. (2022). Prenatal cocaine exposure, early cannabis use, and risky sexual behavior at age 25. *Neurotoxicology and teratology*, 89, 107060. <https://doi.org/10.1016/j.ntt.2021.107060>
- Dos Santos JF, et al. 2018. Maternal, fetal and neonatal consequences associated with the use of crack cocaine during the gestational period: a systematic review and meta-analysis. *Arch Gynecol Obstet*. 298(3):487-503.
- Hoyme HE, et al. 1990. Prenatal cocaine exposure and fetal vascular disruption. *Pediatrics* 85:743-747.
- Jufer RA, et al. 2000. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. *Journal of analytical toxicology*; 24(7), 467-477.
- Karpova N, 2021. Prenatal drug exposure and executive function in early adolescence. *Neurotoxicology and teratology*; 88, 107036.
- Landi N, et al. 2017. Prenatal Cocaine Exposure Impacts Language and Reading Into Late Adolescence: Behavioral and ERP Evidence. *Dev Neuropsychol*. 42(6):369-386.
- Levine TP, et al. 2008. Effects of prenatal cocaine exposure on special education in school-aged children. *Pediatrics* 122 (1): e83-91.
- Lewis BA, et al. 2007. Prenatal cocaine and tobacco effects on children's language trajectories. *Pediatrics* 120(1):e78-85.
- Mayer LC, Nicholls S. 2007. Neurocognitive development in middle-school age and adolescent prenatally cocaine-exposed children. *Birth Def Res (Part A)* 79:381-394.
- Modernel XD, et al. 2017. Use of crack in pregnancy: repercussions for the newborn. *Invest Educ Enferm*. 35(3).
- Montgomery DP, et al. 2008. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. *J Perinatol* 28(11):750-753.
- Morie KP, et al. 2020. Alexithymia, Emotion-Regulation Strategies, and Traumatic Experiences in Prenatally Cocaine-Exposed Young Adults. *The American journal on addictions*; 29(6), 492-499.
- National Institute on Drug Abuse. "Substance Use While Pregnant and Breastfeeding." *National Institute on Drug Abuse*, 2020,
- National Library of Medicine (US), 2006. "Cocaine"
- Ness RB, et al. 1999. Cocaine and tobacco use and the risk of spontaneous abortion. *N Engl Med* 340(5):333-339.s
- Oliveira TA, et al. 2016. Perinatal outcomes in pregnant women users of illegal drugs. *Rev Bras Ginecol Obstet*. 38(4):183-188.
- Pires A, et al 2012. Repeated inhalation of crack-cocaine affects spermatogenesis in young and adult mice. *Inhal Toxicol*. 24(7):439-446.
- Reece-Stremtan S, Marinelli KA. 2015. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. *Breastfeed Med*. 10(3):135-41.
- Richardson GA, et al. 2007. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. *Pediatrics*. 120(4): e1017-1027.
- Richardson GA, et al. 2010. Prenatal cocaine exposure: Effects on mother- and teacher-rated behavior problems and growth in school-age children. *Neurotoxicol Teratol*.
- Richardson GA, et al. 2015. Effects of prenatal cocaine exposure on adolescent development. *Neurotoxicol Teratol*. 49:41-8.

- Roussotte F, et al. 2010. Structural, metabolic, and functional brain abnormalities as a result of prenatal exposure to drugs of abuse: evidence from neuroimaging. *Neuropsychol Rev.*
- Salzwedel A, et al. 2020. Functional dissection of prenatal drug effects on baby brain and behavioral development. *Human brain mapping*; 41(17), 4789–4803.
- Semet M, et al. 2017. The impact of drugs on male fertility: a review. *Andrology* 5:640-63.
- Serino D, et al. 2018. Psychological Functioning of Women Taking Illicit Drugs during Pregnancy and the Growth and Development of Their Offspring in Early Childhood. *J Dual Diagn.* 25:1-13.
- Singer LT, et al. 2000. Neurobehavioral outcomes of cocaine-exposed infant. *Neurotoxicol Teratol* 22(5):653-666.
- Singer LM, et al. 2008. Prenatal cocaine exposure: drug and environmental effects at 9 years. *J Pediatr* 153(1): 105-111.
- Van Gelder MMHJ, et al. 2009. Maternal periconceptional illicit drug use and the risk of congenital malformations. *Epidemiology* 20(1):60-66.
- Weathers WT, et al. 1993. Cocaine use in women from a defined population: prevalence at delivery and effects of growth in infants. *Pediatrics* 91(2):326-239.
- Yazigi RA, et al. 1991. Demonstration of specific binding of cocaine to human spermatozoa. *JAMA* 266:1956-1959.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

CMV

- Akorn Operating Company LLC. 2023. Olopatadine product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f42d26f8-c583-411b-b17f-b3ca9eaba7a2>. Accessed 30 September 2024.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

CMV

Selected References:

- Aselton P, et al. 1985. First-trimester drug use and congenital disorders. *Obstet Gynecol* 65:451-5.
- Check J, et al. 1982. Improvement of cervical mucus factor with guaifenesin. *Fertility and Sterility*, 37(5): 707-708.
- Briggs GG, et al. 2017. *Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk*. 11th ed. Cao Y, et al. 2021. Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case-control study. *BMJ Open*, 11: e053604.
- Check JH, et al. 1982. Improvement of cervical factor with guaifenesin. *Fertil Steril* 37:707-8.
- Dicipinigattis, et al. 2003. Effects of guaifenesin on cough reflex and sensitivity. *Chest Journal*, 126(6): 2178-2181.
- Dude C, et al. 2021. Assessment of the Safety of Common Medications Used During Pregnancy. *JAMA*, 326(23):2421-2422.
- Heinonen OP, et al. 1977. *Birth defects and drugs in pregnancy*. Littleton, MA: Publishing Sciences Group.
- Means G, et al. 2010. Guaifenesin and increased sperm motility: a preliminary case report. *Int J Gen Med*, 4: 13-14.
- PDR.Net. 2024. Guaifenesin-Drug Summary. **PDR.Net** Accessed December 10, 2024. <https://www.pdr.net/drug-summary/Mucinex-guaifenesin-1275>.
- Servey J, et al. 2014. Over-the-Counter Medications in Pregnancy. *Am Fam Physician*, 90(8):548-55.
- Shaw G, et al. 1998. Maternal illness, including fever, and medication use as risk factors for neural tube defects. *Teratology*, 57: 1-7.
- Silva R, Lee J, et al. 2007. Is guaifenesin safe during pregnancy? *J. Family Practice* 56 (8): 669-670.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

CMV

Selected References:

- Amato MP, et al. 2015. Fertility, pregnancy and childbirth in patients with multiple sclerosis: Impact of disease-modifying drugs. *CNS Drugs*. 29:207-220.
- Andersen JB, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. *Eur J Neurol* 30(1):162-171.
- Bridel C, et al. 2014. Update on multiple sclerosis treatments. *Swiss Med Wkly*. 144:w14012.
- Ciplea AI, et al. 2020. Dimethyl fumarate transfer into breast milk. *Ther Adv Neurol Disord*. 13:1756286420968414.
- Gold R, et al. 2015. Delayed-release dimethyl fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. *Neurol Ther*. 4(2):93-104.
- Hellwig K, et al. 2024. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. *Mult Scler* 30(2):209-215.
- Landi D, et al. 2024. Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. *Mult Scler* 30(11-12):1503-1513.
- Leroy C, et al. 2015. Immunosuppressive drugs and fertility. *Orphanet J Rare Dis*. 10:136.
- Lu E, et al. 2014. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. *CNS Drugs*; 28(2):89-94.
- Moccia M, et al. 2023. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. *J Neurol Neurosurg Psychiatry*. 94(9):689-697.
- Tecfidera prescribing information. 2024. Available online at: https://www.tecfiderahcp.com/content/dam/commercial/multiple-sclerosis/tecfidera/hcp/en_us/pdf/Tecfidera_PI.pdf.
- Van Neste M, et al. 20 Very low monomethyl fumarate exposure via human milk: a case report-a contribution from the ConcePTION project. *Front Public Health*. 2;12:1393752.
- Yeh WZ, et al. 2021. Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. *Neurology*. 96(24):e2989-e3002.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.